Industry Type: ALL Conventional Industry High-Tech Industry Service Industry Emerging Industry    Title:  

Raw Material Medicine Manufacturing 2022-Jul Doc　#36540 Industry Report (condensed version) US$100 Demand in the end market remains strong, suggesting active pharmaceutical ingredient firms with niche products will benefit from the restructuring process of the pharmaceutical supply chains in Europe and the United States and generic drug companies in Taiwan. Consequently, the industry climate will be slightly favorable in the second half of 2022. Food Biotechnology Industry 2022-Jun Doc　#36389 Industry Report (condensed version) US$100 COVID-19 may transition to an ordinary seasonal virus in the second half of 2022. Meanwhile, the costs of some materials continue to rise, and there is little room for an improvement in transport capacity worldwide, subduing the industry’s gross margin. Specialized Biotechnology Industry 2022-May Doc　#36242 Industry Report (condensed version) US$100 Efforts to integrate physical stores and e-commerce platforms bear fruit. The move helps the firms explore overseas markets such as the Association of South-East Asian Nations, suggesting sales of some domestic medicated cosmetics will maintain growth. Raw Material Medicine Manufacturing 2022-Jan Doc　#35700 Industry Report (condensed version) US$100 The industry is expected to return to growth track in the first half of 2022 as efforts to explore new markets overseas begin to bear fruit and firms gradually resume production capacity. 2022 Western Medicines and Biopharmaceuticals 2021-Dec Doc　#35332 Annual Report (condensed version) US$150 The coronavirus pandemic will turn into a seasonal influenza, auguring well for Taiwan’s exports sales of western medicines, raw materials and biological medicines. Regenerative Medicine 2021-Nov Doc　#35478 Industry Report (condensed version) US$100 Given the government’s commitment to new policies, the existing cell storage business will continue to grow steadily, accelerate clinical progress in the cell therapy program, and strengthen the competitiveness of Taiwan’s contract manufacturing organizations. As a result, the industry climate is expected to be favorable in 2022. Food Biotechnology Industry 2021-Oct Doc　#35231 Industry Report (condensed version) US$100 Taiwanese firms continue to explore emerging markets, and their efforts to develop the China market is expected to bear fruit. Given a positive outlook for sales at home and abroad, the industry climate will be favorable in the first half of 2022. Raw Material Medicine Manufacturing 2021-Sep Doc　#35098 Industry Report (condensed version) US$100 Most of the countries in emerging markets will continue to grapple with the coronavirus pandemic in the second half of 2021, spurring demand for active pharmaceutical ingredients for antibiotics and anticoagulants. Specialty Biotechnology 2021-Apr Doc　#34340 Industry Report (condensed version) US$100 Demand for base makeup and lip makeup products will remain under pressure as epidemic prevention has become a new normal in Taiwan. However, the industry climate is expected to be slightly favorable. Raw Material Medicine Manufacturing 2021-Apr Doc　#34338 Industry Report (condensed version) US$100 Global demand for antibiotic-specific active pharmaceutical ingredients for the treatment of severely ill COVID-19 patients remains strong. Moreover, the gradual restructuring of the pharmaceutical supply chains in Europe and America augurs well for Taiwan firms dedicated to niche products, helping expand the export markets in the first half of 2021.  First  Previous  Next  Last  In  1  /  6  Page  (Find  54  records)

Copyright (c) 2018 All Rights Reserved by
Taiwan Institute of Economic Research
Taiwan Industry Economics Services
Address: 4Fl., 16-8, Tehui St., Taipei, Taiwan
TEL: 886-2-25865000 ext469; FAX: 886-2-25935543